Aurigene Discovery Technologies Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aurigene Discovery Technologies Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12318
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aurigene Discovery Technologies Ltd (Aurigene), a subsidiary of Dr. Reddy’s Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns integrated drug discovery infrastructure from hit generation to pre-clinical development. Aurigene’s pipeline portfolio consists of products for immunoncology PD-L1 and Vista, TIM-3 and PD1, CD47; precision oncology products IRAK4, NAMPT, KRAS, CDK7; Epigenetics products BET Bromodomain, PRMT5, CBP and P300; and inflammatory product ROR Inverse Agonist. It operates through collaboration with mid-pharma companies. Aurigene is headquartered in Bangalore, Karnataka, India.

Aurigene Discovery Technologies Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Aurigene Discovery Enters into Agreement with Curis 10
Licensing Agreements 12
Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 12
Curis Exercises Option for Licensing Agreement with Aurigene Discovery 13
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 15
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 16
Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 17
Aurigene Discovery Technologies Ltd – Key Competitors 18
Aurigene Discovery Technologies Ltd – Key Employees 19
Aurigene Discovery Technologies Ltd – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Product News 21
03/31/2017: Aurigene to Present Data on CD47-SIRPα interaction program at the AACR 2017 21
03/31/2017: Aurigene to Present Data on MALT-1 Signalling Program at the AACR 2017 22
Clinical Trials 23
Jan 17, 2018: Curis Announces Initiation of Phase 1 Trial of CA-4948, a Small Molecule Inhibitor of IRAK4 Kinase in Patients with Lymphoma 23
Nov 03, 2017: Curis to Present Data On Its Cancer Drug Candidate CA-170 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit 24
Nov 03, 2017: Curis to Present Preclinical Data On Its Cancer Drug candidate CA-327 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit 25
Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017 26
Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress 27
May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting 28
Mar 30, 2017: Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aurigene Discovery Technologies Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aurigene Discovery Enters into Agreement with Curis 10
Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 12
Curis Exercises Option for Licensing Agreement with Aurigene Discovery 13
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 15
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 16
Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 17
Aurigene Discovery Technologies Ltd, Key Competitors 18
Aurigene Discovery Technologies Ltd, Key Employees 19
Aurigene Discovery Technologies Ltd, Other Locations 20
Aurigene Discovery Technologies Ltd, Subsidiaries 20

List of Figures
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aurigene Discovery Technologies Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Aurigene Discovery Technologies Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • RIKEN:製薬・医療:M&Aディール及び事業提携情報
    Summary RIKEN is a research organization that carries out basic and applied science research programs. The organization’s research system consists of strategic research centers, research infrastructure centers, chief scientist system, etc. and a cluster for industry partnerships. Its centers, resear …
  • Dr. Reddy’s Laboratories Limited:企業の戦略・SWOT・財務分析
    Dr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report Summary Dr. Reddy's Laboratories Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • High Peak Royalties Ltd (HPR):企業の財務・戦略的SWOT分析
    High Peak Royalties Ltd (HPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • LG International Corp:企業のM&A・事業提携・投資動向
    LG International Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LG International Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Menarini Asia-Pacific Holdings Pte Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary A. Menarini Asia-Pacific Holdings Pte Ltd (A. Menarini Asia-Pacific), formerly Invida Group Pte Ltd, a subsidiary of A. Menarini Industrie Farmaceutiche Riunite Srl is a biopharmaceutical company that develops consumer health care products. The company operates through its divisions includin …
  • Promotora y Operadora de Infraestructura, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    Promotora y Operadora de Infraestructura, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Promotora y Operadora de Infraestructura, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the comp …
  • Follett Corporation:企業の戦略的SWOT分析
    Follett Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Castle Brands Inc.:企業の戦略・SWOT・財務分析
    Castle Brands Inc. - Strategy, SWOT and Corporate Finance Report Summary Castle Brands Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Indigo Books & Music, Inc.:戦略・SWOT・企業財務分析
    Indigo Books & Music, Inc. - Strategy, SWOT and Corporate Finance Report Summary Indigo Books & Music, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Eu Yan Sang International Ltd:企業の戦略的SWOT分析
    Eu Yan Sang International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Discovery Communications, Inc.
    Discovery Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Discovery Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • African Phoenix Investments Limited:企業の戦略・SWOT・財務情報
    African Phoenix Investments Limited - Strategy, SWOT and Corporate Finance Report Summary African Phoenix Investments Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Devoteam Sa:企業の戦略・SWOT・財務分析
    Devoteam Sa - Strategy, SWOT and Corporate Finance Report Summary Devoteam Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • STATS UK Ltd:企業の戦略的SWOT分析
    STATS UK Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • AstraZeneca Plc (AZN)-製薬・医療分野:企業M&A・提携分析
    Summary AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and n …
  • Minnkota Power Cooperative Inc:発電所・企業SWOT分析
    Minnkota Power Cooperative Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on ke …
  • BEML Ltd:企業の戦略・SWOT・財務分析
    BEML Ltd - Strategy, SWOT and Corporate Finance Report Summary BEML Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Acarix AS-医療機器分野:企業M&A・提携分析
    Summary Acarix A/S (Acarix) is a medical device company that offers design and development of non-invasive cardiac screening products. The company offers non-invasive screening device, CADScor system used to record, process and display heart signals as a patient specific score as the CAD-score on th …
  • Bonduelle Sca:企業の戦略・SWOT・財務分析
    Bonduelle Sca - Strategy, SWOT and Corporate Finance Report Summary Bonduelle Sca - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Hetero Drugs Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Hetero Drugs Ltd (Hetero) is a manufacturer of active pharmaceutical ingredients, intermediate chemicals and finished dosages. The company specializes in process chemistry, API manufacturing, formulation development, manufacturing and commercialization of bio-generics, and also offers custom …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆